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ABSTRACT
Cobalt-chrome alloy is a widely used biomaterial in joint replacements, dental 
implants and spinal rods. Although it is an effective and biocompatible material, 
adverse reactions to metal debris (ARMD) have arisen in a minority of patients, 
particularly in those with metal-on-metal bearing hip replacements. There is currently 
no treatment for ARMD and once progressive, early revision surgery of the implant 
is necessary. Therapeutic agents to prevent, halt or reverse ARMD would therefore 
be advantageous. 
Cobalt ions activate Toll-like receptor 4 (TLR4), an innate immune receptor 
responsible for inflammatory responses to bacterial lipopolysaccharide (LPS) 
resulting in the production of pro-inflammatory cytokines and chemokines. We 
hypothesised that anti-TLR4 neutralising antibodies, reported to inhibit TLR4-
mediated inflammation, could prevent the inflammatory response to cobalt ions in 
an in vitro macrophage cell culture model. 
This study shows that a monoclonal anti-TLR4 antibody inhibited cobalt-mediated 
increases in pro-inflammatory IL8, CCL20 and IL1A expression, as well as IL-8 
secretion. In contrast, a polyclonal antibody did not prevent the effect of cobalt 
ions on either IL-8 or IL1A expression, although it did have a small effect on the 
CCL20 response. Interestingly, both antibodies inhibited cobalt-mediated neutrophil 
migration although the greater effect was observed with the monoclonal antibody.
In summary our data shows that a monoclonal anti-TLR4 antibody can inhibit 
cobalt-mediated inflammatory responses while a polyclonal antibody only inhibits 
the effect of specific cytokines. Anti-TLR4 antibodies have therapeutic potential in 
ARMD although careful antibody design is required to ensure that the LPS response 
is preserved.
INTRODUCTION
Cobalt-chrome alloy is widely used as a biomaterial 
in orthopaedic joint replacements, spinal reconstructive 
rods and dental implants. Over recent years concerns have 
emerged regarding early failure in hip replacements with 
cobalt-chrome metal-on-metal (MoM) bearings. These 
failing joint replacements are associated with high levels 
of cobalt and chromium in the blood and within the joint 
space itself. Clinical reactions include abnormal fluid 
collections, metallosis, muscle and soft tissue necrosis, 
pseudotumours, osteolysis and implant loosening [1]. 
These tissue responses are collectively termed ‘adverse 
reactions to metal debris’ (ARMD) [2]. Analysis of the 
MoM peri-implant tissues reveals a cellular infiltrate 
dominated by macrophages [3] and lymphocytes [4] 
along with high levels of cytokines and chemokines which 
strongly suggests an inflammatory response. 
Currently MoM total hip replacement revision rates 
range from 15% to 35% at 7 years compared to 2% for 
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conventional metal-on-polyethylene devices [5]. Despite 
the high rate of revision for MoM hip replacements there 
are still more than 1 million patients worldwide with 
these hips implanted and un-revised [6], which require 
ongoing surveillance. The major therapeutic option 
for pseudotumours and ARMD is currently removal 
of all cobalt-chrome alloy and revision to a ceramic or 
polyethylene hip implant. This is a more complex surgical 
procedure than primary hip replacements due to the 
erosion bone stock and loss of muscle and soft tissue, 
and post-revision recovery is often slow and incomplete. 
Hip revision for pseudotumours has been associated with 
operative risks comprising 75% blood transfusion, 19% 
recurrent dislocation, 19% nerve palsy, 13% component 
loosening and 40% risk of re-revision [7, 8] causing 
distress to patients and a considerable financial burden 
to the NHS. An adjuvant therapeutic agent that could 
ameliorate or inhibit the initiation of the inflammatory 
signalling cascade that results in ARMD and thus lessen 
the surgical insult or even dampen down ARMD without 
the need for surgical intervention would therefore 
be attractive. Current research into ARMD therapies 
focuses on modulation of the ongoing inflammatory 
response by polarising macrophages towards an anti-
inflammatory phenotype [9] or inhibiting the function of 
pro-inflammatory cytokines such as CCL2 [10] and have 
shown positive results in in vivo models. However they 
are made more complex by the pleiotropic and redundant 
nature of cytokines and chemokines. 
Recent studies by our group and others have shown 
that cobalt ions generated by MoM hip articulation can 
activate the innate immune receptor Toll-like receptor 4 
(TLR4) [11-14] which is most commonly known as the 
receptor for Gram negative bacterial lipopolysaccharide 
(LPS). Cobalt-mediated TLR4 activation increases 
the secretion of pro-inflammatory cytokines such as 
interleukin-8 (IL-8, chemokine (C-X-C motif) ligand 
8 or CXCL8), interleukin-6 (IL-6) and chemokine 
(C-X-C motif) ligand 10 (CXCL10) in macrophages 
and endothelial cells [11, 14]. A small molecule TLR4 
antagonist, CLI-095, is able to prevent these responses 
[14] but its therapeutic use is limited because of its 
intracellular mechanism of action. 
Antibodies represent a successful and rapidly 
evolving therapeutic strategy. Both monoclonal and 
polyclonal anti-TLR4 antibodies are currently under 
investigation as therapeutic agents in the prevention of 
septic shock induced by LPS [15], and a number of anti-
TLR4 antibodies are currently in clinical trials to improve 
test their effectiveness in diseases including rheumatoid 
arthritis [16]. We therefore hypothesised that anti-TLR4 
neutralising antibodies could prevent cobalt-mediated 
TLR4 activation, using changes in cytokine secretion 
and expression by macrophages as markers of receptor 
activation and inhibition. 
RESULTS
Antibody cytotoxicity
MonoMac 6 cells were incubated with 10μg/
ml MAb2-hTLR4 or 5μg/ml PAb-hTLR4 for 16h. 
Cytotoxicity was assessed by trypan blue staining and 
cells were counted using a Luna II automated cell counter. 
MAb2-hTLR4 did not affect MonoMac 6 cells viability 
(Figure 1) while PAb-hTLR4 decreased cell viability from 
100% to 94% (Figure 1). 
Inhibition of cobalt-mediated inflammatory 
responses by a monoclonal anti-TLR4 antibody
TLR4-expressing MonoMac 6 cells have previously 
been shown to upregulate IL-8 secretion and expression 
when challenged with cobalt ions [14] and were therefore 
selected as an in vitro cell model for this study, using 
IL-8 as a marker of TLR4 activation. MonoMac 6 cells 
were pre-treated with 10μg/ml MAb2-hTLR4 for 1h 
prior to 16h stimulation with 0.75mM CoCl2 or 100ng/
ml LPS. IL-8 protein levels were measured by ELISA 
and IL8 expression was quantified by qRT-PCR. CoCl2 
and LPS both significantly increased IL-8 secretion to 
approximately 5000pg/ml (p<0.001) (Figure 2A). Pre-
treatment with MAb2-hTLR4 significantly decreased 
IL-8 secretion to 3000pg/ml in CoCl2-stimulated cells 
(p<0.001) and 4000pg/ml in LPS-stimulated cells. IL8 
gene expression followed a similar pattern with significant 
upregulation in expression following CoCl2 and LPS 
stimulation (both p<0.001) (Figure 2B). MAb2-hTLR4 
significantly inhibited CoCl2-mediated IL8 expression, 
reducing it from 20-fold to 5-fold (p<0001). The 
monoclonal antibody also prevented the IL8 expression 
increase induced by LPS (p<0.001). 
A polyclonal anti-TLR4 antibody does not prevent 
cobalt-mediated IL-8 changes
A polyclonal anti-TLR4 neutralising antibody, PAb-
hTLR4, is reported to inhibit inflammatory responses 
to TLR4 ligands. Using IL-8 expression and secretion 
by MonoMac 6 cells as a marker of inflammation, the 
ability of PAb-hTLR4 to prevent the cellular response to 
cobalt was assessed. MonoMac 6 cells were pre-treated 
with 5μg/ml PAb-hTLR4 for 10 minutes prior to 16h 
stimulation with either 0.75mM CoCl2 or 100ng/ml LPS. 
IL-8 secretion was measured by ELISA and expression by 
qRT-PCR. 
PAb-hTLR4 did not inhibit CoCl2 or LPS-mediated 
IL-8 secretion (Figure 2C) (p>0.4 in both cases). In 
untreated cells there was an increase in IL-8 secretion in 
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Figure 1: Cytotoxicity assay for MAb2-hTLR4 and PAb-hTLR4. MonoMac 6 cells were incubated with 10μg/ml MAb2-hTLR4 
or 5μg/ml PAb-hTLR4 for 16h. A cytotoxicity assay was conducted using trypan blue staining and cell counting on a Luna II automated 
cell counter. Cell viability was 100% in untreated and MAb2-hTLR4-treated cells, and 94% in those incubated with PAb-hTLR4. Images 
on the right are magnified versions of those on the left. 
Figure 2: Effect of monoclonal and polyclonal anti-TLR4 neutralising antibody on cobalt-mediated IL-8 expression 
and secretion. A. MonoMac 6 cells were pre-incubated with 10μg/ml MAb2-hTLR4 for 1h and then stimulated with 0.75mM CoCl2 or 
100ng/ml LPS for 16h. Supernatant was collected and IL-8 secretion was measured by ELISA. B. qRT-PCR was performed to evaluate 
the effect of MAb2-hTLR4 on IL8 expression. C. MonoMac 6 cells were pre-incubated with 5μg/ml PAb-hTLR4 for 10 minutes followed 
by stimulation with 0.75mM CoCl2 or 100ng/ml LPS for 16h. Supernatant was collected and IL-8 secretion measured by ELISA. D. qRT-
PCR was performed to evaluate the effect of PAb-hTLR4 on IL8 expression. Data is representative of three independent experiments and 
statistical significance was calculated by one-way analysis of variance (ANOVA) with Tukey’s test for multiple comparisons comparing 
all samples to each other. 
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the presence of the antibody although this did not reach 
statistical significance (p=0.051). IL8 expression following 
LPS stimulation was inhibited by PAb-hTLR4 (p<0.001) 
(Figure 2D). However the antibody could not prevent the 
effect of cobalt ions on IL8 expression (p=0.095).
MAb2-hTLR4 prevents cobalt-mediated 
expression of CCL20 and IL1A
Using qRT-PCR arrays 4h stimulation of MonoMac 
6 cells with 0.75mM CoCl2 was found to upregulate 
expression of pro-inflammatory CCL20 and IL1A. The 
array results were subsequently validated by TaqMan-
based qRT-PCR. This analysis confirmed a significant 
upregulation in both CCL20 (Figure 3A) and IL1A (Figure 
3B) expression following 4h exposure of MonoMac 6 cells 
to 0.75mM CoCl2 (both p<0.001), showing the potential of 
these genes as targets for studying antibody efficacy.
The ability of MAb2-hTLR4 to inhibit cobalt-
mediated changes in CCL20 and IL1A expression was 
therefore investigated using the same treatment protocol 
as described for the IL-8 assays. CCL20 expression was 
upregulated approximately 10-fold by CoCl2 stimulation 
(p<0.001) whilst the effect of LPS was greater, with a 50-
fold increase in expression (p<0.001) (Figure 4A). MAb2-
hTLR4 significantly decreased expression of CCL20 in 
response to CoCl2 and the positive control LPS (p<0.001 
in both cases). IL1A expression was also significantly 
increased by CoCl2 (p=0.0283) and LPS (p<0.001) (Figure 
4B). In the presence of MAb2-hTLR4 CoCl2-mediated 
IL1A expression was significantly decreased (p=0.0224) 
as was that of LPS (p<0.001). 
A polyclonal anti-TLR4 antibody can inhibit 
other cobalt-mediated inflammatory effects
Expression of CCL20 and IL1A was investigated 
to validate the inability of PAb-hTLR4 to inhibit TLR4 
activation by cobalt ions using the same treatment protocol 
described for the IL-8 assays. CCL20 expression was 
assessed by qRT-PCR and found to be abrogated by the 
polyclonal antibody (Figure 4C) (p<0.001) but there was 
no effect on IL1A (Figure 4D) (p=0.8246). PAb-hTLR4 
inhibited expression of both genes in response to LPS 
stimulation (p<0.001 for CCL20 and p=0.0044 for IL1A). 
Cobalt-mediated neutrophil migration is inhibited 
by TLR4 neutralising antibodies
Inflammatory cell infiltration is a hallmark of MoM 
peri-implant tissues. As IL-8 secretion is significantly 
increased by cobalt ions and IL-8 is chemotactic for 
neutrophils, the effect of cobalt and the neutralising 
antibodies on primary neutrophil migration was assessed. 
MonoMac 6 cells were pre-stimulated with MAb2-hTLR4 
or PAb-hTLR4 as described earlier before 16h stimulation 
with 0.75mM CoCl2 or 100ng/ml LPS. Conditioned media 
was collected and used in a transwell neutrophil migration 
assay. 
Conditioned media from cobalt-stimulated 
MonoMac 6 cells significantly increased neutrophil 
migration (p<0.001) (Figure 5). Both MAb2-hTLR4 
and PAb-hTLR4 pre-incubation significantly inhibited 
this effect (both p<0.001) although the monoclonal 
antibody induced a greater reduction in migration than the 
polyclonal. 
DISCUSSION
This study demonstrates that a monoclonal anti-
TLR4 neutralising antibody (MAb2-hTLR4) inhibits 
pro-inflammatory IL8, IL1A and CCL20 expression and 
IL-8 secretion by MonoMac 6 cells following cobalt 
stimulation. MAb2-hTLR4 provided more effective 
inhibition than the polyclonal antibody PAb-hTLR4 which 
did not prevent cobalt-mediated IL-8 or IL1A responses 
although it did inhibit CCL20 expression. Despite the 
differences in their inhibitory effect both neutralising 
antibodies prevented neutrophil migration in response to 
cobalt stimulation, with a greater effect observed for the 
monoclonal antibody. 
The differences in inhibition between the 
monoclonal and polyclonal antibodies are likely due to the 
fact that cobalt and LPS bind to TLR4 in different ways; 
cobalt binds directly to the receptor within a ‘histidine 
pocket’ composed of histidine residues H431, 456 and 458 
[11] while LPS initially binds LPS binding protein (LBP) 
before transfer across a series of adaptor proteins to the 
receptor itself. If an antibody blocks an adaptor protein 
binding site then it may inhibit LPS without having an 
effect on the cobalt response. However as PAb-hTLR4 
blocked CCL20 expression it may have a small effect on 
receptor homodimerisation which is required for activation 
by both LPS and cobalt ions [11]. 
The differences in cobalt and LPS binding sites 
could be exploited for the development of an antibody 
to prevent ARMD. For an anti-TLR4 antibody to be 
successful in preventing the inflammatory response 
to cobalt ions it is essential that the immunological 
response to LPS is maintained or else there is a high 
risk of overwhelming bacterial infection and potentially 
lethal septic shock. The development of a novel antibody 
targeting the cobalt-specific binding site of TLR4 could 
prevent activation by cobalt ions while still allowing an 
inflammatory response to LPS. 
This study focused on a select group of pro-
inflammatory cytokines and chemokines induced by cobalt 
based on previous work performed by the group. However 
individual cytokine targets are of limited value when 
investigating the potential of a therapeutic agent as it is the 
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Figure 3: CCL20 and IL1A expression following CoCl
2
 stimulation. MonoMac 6 cells were stimulated with 0.75mM CoCl2 for 
4h before qRT-PCR was conducted to assess A. CCL20 and B. IL1A expression. Data is representative of three independent experiments 
and statistical significance was calculated by Student’s t test. 
Figure 4: Effect of MAb2-hTLR4 and PAb-hTLR4 on cobalt-mediated CCL20 and IL1A expression. A. & B. MonoMac 
6 cells were pre-treated with 10µg/ml MAb2-hTLR4 for 1 hour prior to 16h stimulation with 0.75mM CoCl2 or 100ng/ml LPS. RNA 
was isolated and cDNA synthesised by reverse transcription. CCL20 (A) and IL1A (B) expression was quantified by qRT-PCR. C&D. 
MonoMac 6 cells were pre-treated with 5µg/ml PAb-hTLR4 for 10 minutes before 16h stimulation with 0.75mM CoCl2 or 100ng/ml LPS. 
RNA was isolated and cDNA synthesised by reverse transcription. CCL20 C. and IL1A D. expression was quantified by qRT-PCR. Data 
is representative of three independent experiments and statistical significance was calculated by one-way ANOVA with Tukey’s test for 
multiple comparisons comparing all samples to each other. 
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cumulative effect of cytokines and chemokines that leads 
to ARMD. For this reason neutrophil migration assays 
were performed to assess the capacity of the antibodies 
to prevent cobalt-mediated neutrophil recruitment. Both 
antibodies inhibited neutrophil migration; the effect of 
the monoclonal antibody was greater than that of the 
polyclonal which supports the other data described in this 
study. It also indicates that neutrophil chemokines other 
than IL-8 are inhibited by PAb-hTLR4. Additional in 
vitro functional assays or in an in vivo mouse model with 
humanised TLR4 could be used to further investigate these 
effects and antibody efficacy. 
In summary, our data shows that anti-TLR4 
neutralising antibodies can prevent cobalt activation 
of the receptor and subsequent inflammatory cytokine 
upregulation by human macrophages. The design of an 
antibody for ARMD therapy will be critical to provide the 
most effective inhibition of cobalt-mediated inflammation 
while still ensuring that the LPS-binding capacity of TLR4 
is preserved. This work suggests that TLR4 has excellent 
potential as a therapeutic target in the prevention of 
ARMD. 
MATERIALS AND METHODS
MonoMac 6 cells
MonoMac 6 cells are a TLR4-expressing human 
macrophage cell line derived from acute monocytic 
leukaemia. MonoMac 6 cells were cultured in complete 
RPMI-1640 medium supplemented with 10% foetal 
bovine serum (FBS), 2mM L-glutamine, 50 U/ml 
penicillin and 50μg/ml streptomycin (all Sigma-Aldrich, 
Gillingham, UK). 
Metal ion stimulation
Cobalt chloride hexahydrate (CoCl2) was diluted 
in complete cell culture medium and used at 0.75mM, a 
physiological concentration optimised in a previous study 
[14]. TLR4-specific LPS (from E. coli serotype J5, Alexis 
Biochemicals, San Diego, USA) was used at 100ng/ml as 
a positive control for receptor activation. 
Neutralising antibodies
PAb-hTLR4 (Invivogen, San Diego, USA) is a 
polyclonal rat IgG antibody reported to neutralise TLR4 
and prevent activation by its ligands [17]. MAb2-hTLR4 
(Invivogen) is a monoclonal mouse IgG1 antibody (clone 
3C3) reported to neutralise TLR4 and prevent receptor 
activation by agonists [15]. 
Cytotoxicity
Cytotoxicity was assessed by trypan blue staining; 
10μl trypan blue dye (Logos Biosystems, Anyang-City, 
South Korea) was mixed with 10μl cell suspension and the 
number of live and dead cells was counted using a Luna-II 
Automated Cell Counter (Logos Biosystems). Data was 
normalised to 100% viability for untreated cells. 
Figure 5: Anti-TLR4 neutralising antibodies inhibit cobalt-mediated neutrophil chemotaxis. MonoMac 6 cells were pre-
treated with 10µg/ml MAb2-hTLR4 for 1 hour or 5µg/ml PAb-hTLR4 for 10 minutes before 16h stimulation with 0.75mM CoCl2 or 100ng/
ml LPS. Supernatant was collected and chemotactic properties assessed using a transwell neutrophil migration assay. Data is representative 
of three independent experiments and statistical significance was calculated by one-way ANOVA with Tukey’s test for multiple comparisons 
comparing all samples to each other.
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Quantitative real-time PCR (qRT-PCR)
RNA was isolated using a Qiagen RNeasy Mini 
kit (Qiagen, Venlo, Netherlands) and cDNA synthesized 
using Superscript III reverse transcriptase (ThermoFisher 
Scientific, Massachusetts, USA). qRT-PCR was performed 
using TaqMan gene expression probes (ThermoFisher 
Scientific). Each reaction contained 5µl TaqMan Gene 
Expression Mastermix (ThermoFisher Scientific), 
8µl diluted cDNA, 2.5µl nuclease-free H2O and 0.5µl 
TaqMan Gene Expression Assay. No-template controls 
containing 8µl H2O instead of cDNA were included for 
all assays. All target genes were normalised to GAPDH 
as a housekeeping gene. Reactions were performed in 
triplicate. 
ELISA
Enzyme-linked immunosorbent assays (ELISA) 
were used to quantify cytokine secretion by MonoMac 
6 cells. IL-8 secretion was quantified using a Human 
IL-8 ELISA kit (Peprotech, London, UK) as described 
previously [14]. 
Transwell neutrophil migration assay
Neutrophils were isolated from the whole 
blood of healthy volunteers by dextran sedimentation 
(Dextran T500, Pharmacosmos, Holbaek, Denmark) 
and centrifugation on Percoll (GE Healthcare, 
Buckinghamshire, UK) density gradients as previously 
described [18]. 
A 24-well companion plate (VWR International, 
Pennsylvania, USA) was blocked with 1% bovine serum 
albumin (BSA) (Sigma Aldrich) for 1 hour after which 
800μl conditioned media from stimulated MonoMac 6 
cells was added to each well. A cell culture insert with 
3μm pore filter (VWR International) was placed in each 
well and 500,000 neutrophils added to the upper chamber 
of each insert. The plate was incubated at 37oC for 2 hours 
to allow for cell migration. Excess media was removed and 
filters incubated overnight in 100% methanol. Filters were 
stained with haematoxylin for 30 minutes and washed in 
Scott’s tap water for 10 minutes. This was followed by 
dehydration in increasing ethanol concentrations (50, 75, 
90 and 100%) for 2 minutes each. Filters were air-dried for 
a minimum of three hours and were excised and mounted 
using DPX mountant. Adhered neutrophils were counted 
at x40 magnification. 
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism 6.0 (GraphPad Software Inc., San Diego, USA). 
All error bars show the standard error of the mean (SEM) 
unless otherwise stated. The analysis method is described 
for each individual experiment. Statistical significance is 
shown as follows *=p<0.05, **=p<0.01, ***=p<0.001. 
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